Comparison of in vitro fertilization cycles in couples with human immunodeficiency virus type 1 infection versus noninfected couples through a retrospective matched case-control study

Caroline Aimone Vianna, M.D., a Charlotte Dupont, Pharm. D., Ph.D., a Lise Selleret, M.D., b Ana Canestri, M.D., c Rachel Levy, M.D., Ph.D., a and Rahaf Haj Hamid, M.D., a

a Biologie de la Reproduction - Centre d’Etude et de Conservation des Oeufs et du Sperme humains, b Service de Gynécologie Obstétrique - Médecine de la Reproduction, and c Service Maladies Infectieuses et Tropicales, Hôpital Tenon, Paris, France

Objective: To compare in vitro fertilization (IVF) outcomes in couples in which at least one partner is human immunodeficiency virus (HIV) positive with that of couples in which neither partner is HIV-positive.

Design: Retrospective matched case-control study.

Setting: Fertility center at Tenon Hospital, Paris, France.

Patient(s): A total of 179 IVF cycles in couples infected with HIV-1 and 179 IVF cycles in control couples.

Intervention(s): Ovarian stimulation, oocytes retrieval, IVF (standard and microinjection), embryo transfer, pregnancy, and live birth follow-up.

Main Outcome Measure(s): Live birth rate and IVF outcomes

Result(s): The first comparison between HIV and non-HIV couples showed poorer outcomes in the HIV group (higher administered gonadotropin doses and longer stimulation periods, lower cumulative pregnancy and live birth rates, among other things). A subgroup analysis was performed in addition. No differences were found in the “men HIV” group compared with the controls. In contrast, poorer outcomes in the “women HIV” and “women and men HIV” groups were shown in terms of administered doses, duration of stimulation, and number of oocytes retrieved. For the “women HIV” group, lower cumulative clinical pregnancy and live birth rates were found.

Conclusion: The data suggested that couples with HIV-positive women have poorer medically assisted procreation outcomes than couples with non-HIV-infected women. Therefore, physicians should pay particular attention to couples with HIV-positive women.

(Fertil Steril Rep® 2021;2:376–85. ©2021 by American Society for Reproductive Medicine.)

Key Words: Assisted reproductive technology, human immunodeficiency virus, in vitro fertilization outcomes

Discuss: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/posts/xfre-d-20-00264

In 2017, the number of people living with human immunodeficiency virus (HIV) reached 36.9 × 10^6 people (49.3% women) worldwide. Despite global actions to prevent it, and notwithstanding a decrease in the number of new cases in 2017 (1.8 × 10^6 compared with 3.4 × 10^6 in 1996), the number is still growing (1). A decrease in deaths related to opportunistic pathologies of acquired immunodeficiency syndrome (1.9 × 10^6 in 2004 compared with 940,000 in 2017) has been accomplished in recent years thanks, in particular, to the use of antiretroviral therapy (1). In France, the number of new infections discovered has been stable since 2011 (6,200 new cases in 2018, 35% women).
Absence of genital infection, in undetectable viral load for 6 months, and long-term antiretroviral therapy with good compliance follows (2).

According to the latest Morlat report (2018), antiretroviral therapies (ART) and serodiscordant partners must be carefully managed. Criteria for access to ART in France (27) are established to orient couples as much as possible. This care is a completely legitimate place in the care of HIV-positive couples. This point needs to be addressed as early as possible in this care. The aim is to inform couples about the possibilities of conceiving through natural procreation or medically assisted procreation (assisted reproductive technology [ART]), about antiretroviral treatments and their undesirable and/or teratogenic effects, and the need to adapt therapies and implement strategies to avoid the risks of sexual and/or mother-child transmission.

The risk of transmission has been assessed in many studies (4, 5), including a meta-analysis (6) of 2,848 people infected with HIV. The investigators showed the absence of viral transmission in serodiscordant couples under optimal antiretroviral treatment conditions (undetectable plasma load for >6 months). In 2008, Sauer et al. (7) studied 10 years of in vitro fertilization (IVF) care to HIV-positive men and seronegative women in the United States. They observed no maternal or neonatal HIV infections.

Thanks to diverse measures undertaken during pregnancy, labor, delivery, and the postnatal period, including antiretroviral therapy, cesarean delivery when indicated, and no breastfeeding, the vertical transmission rate of HIV remains low. Indeed, in 2018, the Centers for Disease Control and Prevention surveillance showed that of 1,042,270 cases of diagnosed HIV at the end of 2018, <1% were among children with diagnosed perinatal HIV (8).

The effectiveness of antiretroviral treatments and the very low rate of maternal-fetal transmission (8) have made natural procreation the first choice for certain serodiscordant couples wishing to conceive. The virologic conditions required, according to the latest Morlat report (2018), are as follows (2):

- Long-term antiretroviral therapy with good compliance
- Undetectable viral load for 6 months
- Absence of genital infection, inflammation, or genital wounds in both partners
- Fertility conditions that will not delay support with ART in case of proven infertility factors

When ART is needed, the reproductive technique is based on the fertility criteria used in the general population. Intratubal insemination is used in the case of normal sperm parameters and absence of tubal abnormalities. Otherwise, IVF or intracytoplasmic sperm injection is used according to the sperm parameters. HIV-positive patients must meet the management criteria for ART, and serodiscordant partners must have negative HIV serology.

The prevalence of infertility among those with HIV was studied from 1994 to 2002 in a prospective cohort in the United States, and the results showed that HIV-positive women were less likely to conceive than seronegative women (pregnancy rates 7.4% vs. 15.2% per 100 person-years) (10). On the other hand, HIV-1-infected male patients showed altered semen parameters compared with controls. This was related to the infection and to antiretroviral treatments (11, 12).

There are only a few studies of IVF results in couples living with HIV. Observational studies (7, 13–16) evaluated the pregnancy rate per cycle in this population, which ranged from 9.2% to 45%. Other retrospective case-control studies compared IVF outcomes in HIV-infected and noninfected patients. Some studies (17–20) found lower rates of clinical pregnancy and/or implantation and live birth rates in the HIV group (women HIV-positive or men and women HIV-positive). Other studies (21–24) found no significant difference or even better results in couples in which the man was HIV-positive (25). Because of the discordant results, different biases, and low numbers in these studies, it is difficult to draw any conclusions with certainty.

In 2016, 209 cycles of IVF for couples living with HIV were made in France, which resulted in 21 active pregnancies, 21 deliveries, and 24 live births (26). Our reproductive health care center has been treating HIV-positive couples since 2012. Our interest in this topic is to increase the literature data, to better understand the influence of HIV infection on the fertility of seropositive patients, and to improve the management of these couples by orienting them as well as possible.

MATERIALS AND METHODS

Study Design

This was a single-center case-control retrospective study with standardization of the control population on different adjustment criteria. The study period included the ovarian stimulations that resulted in oocyte retrieval from January 1, 2013, to March 4, 2018, in the fertility center of Tenon Hospital (APHP-Paris).

Ethics

This study was approved by the local ethics committee within the Avicenne health care establishment on April 21, 2020, under the protocol number: CLEA-2020-108 and had no source of funding.

Inclusion/Exclusion Criteria

All IVF cycles performed during the study period at Tenon Hospital were included in our study. Couples supported in our center meet the criteria for access to ART in France (27). The “case” group was composed of couples with HIV infection: the woman, the man, or both members of the couple were infected. Couples could be coinfected with hepatitis B virus (HBV) or hepatitis C virus (HCV). The HIV-positive patients must meet the management criteria defined by the decrees relating to the best-practice methods in ART (27):
Couples must be followed by a multidisciplinary team throughout their care.

Couples must have a CD4 T-cell count > 200/μL and an undetectable HIV viral load on two successive assessments at 3-month intervals in the 6 months preceding the treatment, then an undetectable HIV viral load every 3 months during the medical care.

Serodiscordant couples must have negative HIV serology in the HIV-negative partner 15 days preceding oocyte retrieval.

The “control” group was composed of couples who were not infected with HIV, HBV, or HCV and were patients of our center. In vitro fertilization cycles with gamete donation were excluded from our study.

### Matched Criteria and Studied Groups

To overcome the main confounding factor, each IVF cycle in the HIV group was matched with an IVF cycle in the control group according to the following criteria: woman’s age; IVF technique (conventional or with microinjection); etiology of infertility (tubal, ovulatory, or decreased ovarian reserve, masculine, endometriosis, idiopathic, or mixed female and male factors); rank of the IVF cycle; type of infertility (primary or secondary); and body mass index of the woman.

The HIV group was composed of opposite-sex couples with at least one HIV-positive member. The control group consisted of opposite-sex couples in which neither member was HIV-positive.

The first comparison carried out was between HIV couples and non–HIV couples. Then analysis in subgroups was made (women HIV vs. Women non–HIV, Men HIV vs. Men non–HIV, and Women and Men HIV vs. Couples non–HIV).

### In Vitro Fertilization Cycle Procedure

Before the IVF cycle, a complete physical checkup was carried out on the two members of the couple. None of our non–HIV patients used pre-exposure prophylaxis (PrEP) during the IVF cycle.

The stimulation protocol was chosen according to the woman’s ovarian reserve, her age, and any previous stimulation to achieve the best ovarian response and to avoid ovarian hyperstimulation. The long agonist protocol was usually chosen for women with normal ovarian reserve. This protocol combines pituitary desensitization with pituitary gonadotropin-releasing hormone (GnRH) agonist, in the mid-luteal phase of the previous cycle, prior to ovarian gonadotropin stimulation. For poor-responders, the protocol chosen was the short agonist, which combines gonadotropins in high doses and GnRH agonists to take advantage of the “flair-up” effect of the latter. The antagonist protocol was chosen for hyper-responders at risk for ovarian hyperstimulation. This protocol combines the use of gonadotropins and the introduction of GnRH antagonists in the mid-follicular phase.

Stimulation monitoring was performed on the seventh day by endovaginal ultrasound with counting and measurement of growing follicles, coupled with estradiol, luteinizing hormone, and progesterone blood levels. This ultrasound and biological surveillance were repeated as many times as necessary.

The onset of ovulation was triggered when there were at least three follicles > 17 mm and an estradiol level > 150–200 pg/mL per mature follicle. This was performed by recombinant human chorionic gonadotropin (Ovitrelle; Merck Serono S.p.A., Modugno, Italy) or GnRH analog in antagonist protocols only (Decapeptyl; Ferring Pharmaceuticals, Italy). Oocyte retrieval was performed in the operating room and under general anesthesia 36 hours after the triggering of ovulation.

The sperm samples were taken at the laboratory after a period of sexual abstinence of 2–7 days. The fresh sperm was treated on a density gradient (PureSperm; Nidacon International, Gothenburg, Sweden), followed by a pellet wash in 2 mL of IVF medium (Universal IVF Medium; Origio, Malov, Denmark).

When the man was infected with HIV, a sperm freeze was performed prior to the IVF cycle associated with a detection test of the virus in seminal plasma and/or sperm preparation for virological validation. In case of positive viral load in seminal plasma but < 100,000 copies/mL, a straw was thawed to perform HIV ribonucleic acid testing by the virology laboratory. If HIV ribonucleic acid was found in the final fraction, the initially frozen flasks for ART could not be used and were destroyed.

Conventional IVF or microinjection of spermatozoa was performed according to sperm parameters and based on previous IVF cycles. In our fertility center, the embryo transfer was performed on day 2 or 3 after oocyte retrieval. Supernumerary embryos of good quality (good development kinetics and fragmentation < 30%) were frozen on day 2 or 3. Embryos that could not be transferred or frozen on day 2 or 3 were left in culture and could then be frozen on day 5 or 6 if they reached the blastocyst stage. The number of embryos to be transferred was chosen according to the characteristics of the couple (age of the woman, duration of infertility, rank of IVF cycle, type of infertility) and the embryo quality. Luteal phase support was provided by the daily administration of vaginal progesterone (200 mg three times a day) from the evening of oocyte retrieval.

### Data Collection and Statistical Analysis

The main outcome was the live birth rate. The secondary end points were the following: stimulation data, including total doses of gonadotropins, duration of stimulation, and hormonal assays at triggering; and data from IVF cycles, including the number of oocytes collected, the fertilization rate, the number of embryos obtained (transferred, frozen), the implantation rate, the clinical pregnancy rate, the multiple pregnancy rate, and cumulative rates of clinical pregnancy and live birth, among others.

Data were extracted from “Medifirst” software in an Excel file. The quantitative variables were expressed as mean ± SD and the statistical comparison was performed using a Student’s t-test. The X² test (+/- Yates’ correction) or Fisher’s exact test were used for the comparison of nominal qualitative data when appropriate. All tests were performed bilaterally and P < .05 was considered significant.
RESULTS

During the inclusion period, 179 IVF cycles of couples living with HIV met our criteria and were able to be included. Among these IVF cycles, 97 were in serodiscordant couples in which the woman was HIV-positive, 60 in serodiscordant couples in which the man was HIV-positive, and 22 in couples in which both were HIV-positive. Some couples have infections: one woman with HBV (1.56% of the subgroup), and one man with HCV (2.71% of the subgroup). Within the subgroup, there were four couples with co-infections; one woman with HBV (1.56% of the subgroup), two men with HBV (3.13% of the subgroup), and one man with HCV (1.56% of the subgroup). Within the “men HIV” subgroup, six couples had coinfections: three men with HCV (7.89% of the subgroup) and three women with HBV (7.89% of the subgroup). Within the subgroup “women and men HIV,” three couples were coinfected: two men with HBV (13.33% of the subgroup) and one man with HCV (6.6% of the subgroup).

The control group consisted of 179 IVF cycles in 179 couples with no infection, selected according to the matched criteria mentioned previously. During our study period, 73 frozen embryo transfers were performed in HIV couples and 99 in non-HIV couples.

Population characteristics of patients living with HIV and controls are presented in Table 1. No statistical difference was found between the two groups. The characteristics of the subgroups (“women HIV”, “men HIV”, or “women and men HIV”) and their controls are presented in Supplemental Table 1 (available online). Women in the “men HIV” subgroup had a baseline estradiol level significantly lower than that in the control women. Women in the “women and men HIV” group had significantly higher estradiol levels than women controls. The other parameters were comparable for the three groups.

Concerning the antiretroviral therapy, 128 patients (97%) were under treatment at the beginning of the procedure: 66 patients (51.56%) were treated with the association of 2 nucleoside reverse transcriptase inhibitors (NRTIs) and 1 protease inhibitor, 30 patients (23.44%) with the association of 2 NRTIs and 1 non-nucleoside reverse transcriptase inhibitor, 12 patients (9.38%) with 2 NRTIs and 1 integrase inhibitor, 6 patients (4.68%) had a monotherapy of protease inhibitors, and 14 patients (10.94%) with different “other” associations.

### TABLE 1

| Characteristics of HIV population and controls. | HIV | Controls | P value |
|-----------------------------------------------|-----|----------|---------|
| Number of IVF cycles                          | 179 | 179      |         |
| Women Age (years)                             | (179) 37 ± 3.57 | (179) 36.9 ± 3.43 | .71<sup>c</sup> |
| Women BMI (kg/m²)                             | (172) 25.7 ± 4.88 | (179) 25.3 ± 4.47 | .36<sup>c</sup> |
| Technique<sup>ab</sup>                        |     |          |         |
| ICSI                                          | 86 (48%) | 85 (47%) | .84<sup>d</sup> |
| IVF                                           | 93 (52%) | 94 (53%) |         |
| Rank of IVF cycle<sup>b</sup>                 |     | 1<sup>d</sup> |         |
| 1<sup>st</sup>                                | 114 (63%) | 114 (63%) |         |
| 2<sup>nd</sup>                                | 43 (24%) | 43 (24%) |         |
| ≥ 3<sup>rd</sup>                              | 22 (13%) | 22 (13%) |         |
| Infertility<sup>b</sup>                       |     | 1<sup>d</sup> |         |
| Primary                                       | 107 (60%) | 107 (60%) |         |
| Secondary                                     | 72 (40%) | 72 (40%) |         |
| Infertility etiology<sup>b</sup>              |     | .12<sup>a</sup> |         |
| Tubal                                         | 56 (31%) | 47 (26%) |         |
| Anovulation                                   | 7 (4%) | 4 (3%) |         |
| DOR                                           | 28 (16%) | 25 (14%) |         |
| Male                                          | 18 (10%) | 33 (18%) |         |
| Male and female factors                       | 13 (7%) | 22 (12%) |         |
| Endometriosis                                 | 8 (5%) | 10 (6%) |         |
| Idiopathic                                    | 49 (27%) | 38 (21%) |         |
| AMH (ng/mL)<sup>a</sup>                      | (163) 2.71 ± 10.36 | (169) 2.86 ± 3.77 | .61<sup>c</sup> |
| FSH (mU/mL)<sup>a</sup>                      | (165) 8.24 ± 2.89 | (165) 7.3 ± 11.24 | .08<sup>c</sup> |
| E2 (pg/mL)<sup>a</sup>                       | (163) 50.7 ± 33.76 | (153) 57 ± 66.36 | .27<sup>c</sup> |
| LH (mU/mL)<sup>b</sup>                       | (163) 6.2 ± 7.21 | (145) 5.42 ± 9.90 | .14<sup>c</sup> |
| PRL (ng/mL)<sup>b</sup>                      | (108) 22.1 ± 19.29 | (98) 18.7 ± 11.53 | .12<sup>c</sup> |

Note: AMH = antimüllhormone; BMI = body mass index; DOR = decreased ovarian reserve; E2 = estradiol; FSH = follicle stimulating hormone; HIV = human immunodeficiency virus type 1; ICSI = intracytoplasmic sperm injection; IVF = in vitro fertilization; LH = lutenizing hormone; PRL = prolactin.

<sup>a</sup> Values are (number of IVF cycles) average ± SD.
<sup>b</sup> Values are number of IVF cycles (percentage).
<sup>c</sup> Student’s t-test.
<sup>d</sup> ¥² test.
<sup>e</sup> Yates’ corrected ¥².

Vianna. HIV and ART, a retrospective study. Fertil Steril Rep 2021.
Table 2 presents the comparison between the HIV group and the non–HIV control group. The cumulative rates of clinical pregnancy and live birth were lower among couples living with HIV (P = .03 and P = .02, respectively). In couples with HIV, we noticed more fresh transfer cancellations than in the non–HIV group (P = .045). No IVF cycle cancellation occurred in either groups.

The initial and total doses of gonadotropins used were higher in the HIV group than those in the control group (P = .02 and P = .03, respectively). In addition, the duration of stimulation was longer (P = .001) and the thickness of the endometrium was significantly lower in the HIV group (P = .03).

The fertilization rate, the cleavage rate, and the average number of good quality embryos were significantly lower in the HIV group compared with those in the controls (P = .009, P = .002, and P = .02, respectively). Other parameters were comparable (P ≥ .05).

In a second step, a subgroup study was conducted to clarify the influence of HIV on fertility according to the infected partner. In the “women HIV” subgroup, regarding the IVF outcomes, we found the following: the clinical pregnancy rate per fresh embryo transfer, the live birth rate per oocyte retrieval (all cycles excluding freeze-all: fresh transfer, retrieval without oocyte, cancelled transfer), the live birth rate per transfer (fresh and frozen transfers), the cumulative clinical pregnancy rate, and live birth rate per transfer (fresh and frozen transfers), the cumulative pregnancy rate per fresh transfer, the live birth rate/fresh transfer, the clinical pregnancy rate/fresh transfer, the live birth rate/fresh transfer, the implantation rate, the fertilization rate, the cleavage rate, the average number of embryos collected, the number of mature oocytes, the cleavage rate were significantly lower in HIV-infected women compared with those in controls (19.6% vs. 10.3%, P < .05) because of an absence of available embryos to transfer. The number of oocytes collected and the cleavage rate were significantly lower in HIV-positive women compared with those in controls (P = .02).

In the “women and men HIV” subgroup, the number of oocytes collected, the number of mature oocytes, the cleavage rate, the fertilization rate, and the average number of embryos of acceptable quality were all significantly lower compared with those of controls (P = .004, P = .03, P < .001, P = .009, P = .005, respectively). The fresh transfer cancellation rate was higher in the subgroup “women and men HIV”
groups are shown in Tables 3 and 4. In the subgroup analysis (Supplemental Table 2, available online), no significant difference was found between the subgroups (Table 4).

The same significant differences were found in the “women HIV” and “men and men HIV” subgroups compared with their control population; for the two subgroups, the total dose of gonadotropins was greater (P = .007 and P = .003, respectively), the duration of stimulation was longer (P = .03 for both), and the initial dose of gonadotropins was higher (P = .02 and P = .003, respectively) than those in the control group. In contrast, the hormonal assay results (estradiol, progesterone, luteinizing hormone), the number of expected follicles, and the thickness of the endometrium at triggering of ovulation were comparable in the subgroup analysis (P ≥ .05). The data of these two subgroups are shown in Tables 3 and 4. In the “men HIV” subgroup, no significant differences from the control group results were found (P ≥ .05) for the studied parameters (Supplemental Table 2, available online).

**DISCUSSION**

In our study, we were able to show several significant differences in the outcomes of IVF cycles in our population of couples with HIV infection compared with control couples without HIV, with a decrease in fertility in the groups of HIV-positive women. The choice of controls in our study was made based on six matched criteria: woman’s age and body mass index, the type of infertility of the couple (primary or secondary), the rank of the IVF cycle, the type of technique used (conventional IVF or ICSI), as well as the etiology of the infertility. These criteria are factors that may affect the outcomes of ART. The selected controls allowed us to overcome certain biases and obtain comparable populations to study the influence of HIV infection on the outcomes of IVF cycles.

Previous studies have already approached this subject. Descriptive studies (7, 13–16, 28) found lower pregnancy rates per cycle in the population with HIV, but those studies did not have a control group. Other case-control studies

### Table 3

| Outcome | Women HIV | Controls | P value |
|---------|-----------|----------|---------|
| Number of IVF cycles | 97 | 97 | .007<sup>a</sup> |
| Total dose of gonadotropins used (IU)<sup>a</sup> | 3245 ± 1443 | 2726 ± 1165 | .007<sup>c</sup> |
| Duration of stimulation (days)<sup>a</sup> | 11.1 ± 2.4 | 10.5 ± 1.7 | .03<sup>c</sup> |
| Initial dose of gonadotropins<sup>a</sup> | 286 ± 111 | 252 ± 90 | .02<sup>c</sup> |
| Estradiol at trigger (pg/mL)<sup>a</sup> | 1871 ± 1040 | 2219 ± 1260 | .15<sup>c</sup> |
| Progesterone at trigger (ng/mL)<sup>a</sup> | 0.78 ± 0.44 | 0.88 ± 0.63 | .38<sup>c</sup> |
| LH at trigger (IU/mL)<sup>a</sup> | 1.6 ± 2.08 | 1.72 ± 1.61 | .59<sup>c</sup> |
| Number of follicles expected at trigger<sup>a</sup> | 9 ± 6.4 | 9.6 ± 6.7 | .63<sup>c</sup> |
| Endometrium thickness at trigger (mm)<sup>a</sup> | 9.7 ± 1.9 | 10.2 ± 2.51 | .16<sup>c</sup> |
| Number of oocytes retrieved<sup>a</sup> | 8.6 ± 5.6 | 10.5 ± 6.9 | .04<sup>c</sup> |
| Number of oocytes in MII<sup>a</sup> | 6.2 ± 4.2 | 8.6 ± 5.8 | .002<sup>c</sup> |
| % 3PN/nombre of oocytes in MII | 7.9 | 3.8 | .04<sup>c</sup> |
| Fertilization rate (%) | 61.6 | 68.5 | .11<sup>c</sup> |
| Cleavage rate (%) | 62 | 71 | .04<sup>c</sup> |
| Number of transferred embryos<sup>b</sup> | 1.2 ± 0.9 | 1.3 ± 0.8 | .44<sup>c</sup> |
| Number of frozen embryos<sup>b</sup> | 1.05 ± 1.8 | 1.47 ± 2.1 | .13<sup>c</sup> |
| Number of good quality embryos<sup>b</sup> | 2.25 ± 2.0 | 2.8 ± 2.1 | .09<sup>c</sup> |
| Biochemical pregnancy rate/fresh transfer<sup>b</sup> | 17.6% | 21.1% | .6<sup>d</sup> |
| Implantation rate<sup>b</sup> | 7.7% | 13.5% | .14<sup>c</sup> |
| Clinical pregnancy rate/fresh transfer<sup>b</sup> | 8.8% | 21.1% | .04<sup>d</sup> |
| Live birth rate/fresh transfer<sup>b</sup> | 4.4% | 15.8% | .05<sup>d</sup> |
| Fresh transfer cancellation rate<sup>b</sup> | 19.6% | 10.3% | .007<sup>d</sup> |
| Live birth rate/oocyte retrieval (without the freeze-all)<sup>b</sup> | 3.6% | 15.1% | .02<sup>d</sup> |
| Twin pregnancy rate<sup>b</sup> | 3.3% | 6.6% | .18<sup>c</sup> |
| Twin live birth rate<sup>b</sup> | 66.7% | 8.3% | .08<sup>f</sup> |
| Clinical pregnancy rate/fresh and frozen transfer<sup>b</sup> | 15.7% | 24.8% | .07<sup>d</sup> |
| Live birth rate/fresh and frozen transfer<sup>b</sup> | 8.7% | 18.2% | .03<sup>d</sup> |
| Remaining frozen embryos (%) | 24.5 | 25.2 | .9<sup>d</sup> |
| Cumulative live birth rate<sup>b</sup> | 10.3% | 25.8% | .005<sup>d</sup> |
| Cumulative clinical pregnancy rate<sup>b</sup> | 18.6% | 35.1% | .03<sup>d</sup> |

Note: “Women HIV” were couples in which the women were HIV-positive. HIV — human immunodeficiency virus type 1; IVF — in vitro fertilization; LH — luteinizing hormone; MII — metaphase II; PN — pronuclei.

<sup>a</sup> Values are (number of IVF cycles) average ± SD.
<sup>b</sup> Values are (number of IVF cycles) percentage.
<sup>c</sup> Student’s t-test.
<sup>d</sup> X<sup>2</sup> test.
<sup>e</sup> Yates’ corrected X<sup>2</sup>.
<sup>f</sup> Fisher’s exact test.

Vianna. HIV and ART, a retrospective study. Fertil Steril Rep 2021.
were conducted by-standardizing their control population according to the age of the woman (18, 20, 21, 24, 25); the results of these studies were sometimes discordant. In 2016, Stora (19) conducted a study of the influence of HIV infection on the IVF cycle outcomes in 82 couples by standardizing the control population on more criteria than in previous studies (woman’s age, type and etiology of infertility, date of the oocyte retrieval, rank of the cycle). The investigators found significantly lower clinical pregnancy rate in HIV-infected women compared with that in controls (6% vs. 30%, P < .02). In a women’s age-adjusted study in 2005, Terriou et al. (22) showed that the total gonadotropin dose, the duration of stimulation, and the cancellation rate were significantly higher, and the clinical pregnancy rate was much lower in the “women HIV” group compared with controls. In 2016, in a retrospective case-control study, Stora et al. (19) compared 82 couples who were HIV-positive with 82 seronegative couples standardized on several criteria (age of the woman, etiology and type of infertility, the rank and technique of the IVF cycle). In the “women HIV” group, implantation rate, clinical pregnancy rate (by transfer and by oocyte retrieval), and live birth rate (by transfer) were significantly lower compared with those of controls. In 2017, Vankerkem et al. (20) found similar results in a case-control study (higher

| TABLE 4 |

| Outcome                                                                 | Women and Men HIV | Controls | P value |
|------------------------------------------------------------------------|-------------------|----------|---------|
| Number of IVF cycles                                                  | 22                | 22       | .28     |
| Total dose of gonadotropins used (IU)                                 | (21) 4013 ± 1690  | (22) 2603 ± 1233 | .003*   |
| Duration of stimulation (days)                                        | (22) 11.1 ± 2     | (22) 10.5 ± 1.7 | .03*    |
| Initial dose of gonadotropins                                         | (21) 334 ± 129    | (22) 234 ± 79  | .003*   |
| Estradiol at trigger (pg/mL)                                          | (20) 1556 ± 746   | (22) 2241 ± 1506 | .07*    |
| Progesterone at trigger (ng/mL)                                       | (20) 1.26 ± 0.32  | (22) 0.79 ± 0.31 | .15*    |
| LH at trigger (IU/mL)                                                 | (20) 1.71 ± 0.56  | (22) 0.79 ± 1.18 | .004*   |
| Number of oocytes collected at the oocyte retrieval                    | (20) 6.9 ± 4      | (22) 11.2 ± 7.9 | .18*    |
| Endometrium thickness at trigger (mm)                                 | (15) 9.2 ± 3.7    | (22) 10.5 ± 1.4 | .11*    |
| Number of oocytes retrieved                                           | (22) 6.7 ± 4.4    | (22) 11 ± 4.9  | .004*   |
| Number of oocytes in MII                                               | (22) 5.2 ± 3.4    | (22) 8.5 ± 3.7 | .004*   |
| % 3PN/nombre of oocytes in MII                                         | 4.7               | 6.3       | .53*    |
| Fertilization rate (%)                                                | 39.6              | 62.9     | .009*   |
| Cleavage rate (%)                                                     | 35                | 66       | <.001*  |
| Number of transferred embryos                                         | (22) 0.8 ± 0.9    | (22) 1.6 ± 0.7 | .002*   |
| Number of good quality embryos                                        | (22) 0.54 ± 1.1   | (22) 1 ± 1.2 | .2*     |
| Biochemical pregnancy rate/fresh transfer                             | (2) 16.7%         | (5) 25%   | .68*    |
| Implantation rate                                                      | (2) 11.1%         | (5) 14.3%  | 1*      |
| Clinical pregnancy rate/fresh transfer                                | (2) 16.7%         | (4) 20%   | 1*      |
| Live birth rate/fresh transfer                                        | (1) 8.3%          | (4) 20%   | .62*    |
| Fresh transfer cancellation rate                                       | (8) 40%           | (1) 5%    | .02*    |
| Live birth rate/oocyte retrieval (without the freeze-all)             | (1) 5.6%          | (4) 19%   | .35*    |
| Twin pregnancy rate                                                   | (0) 0%            | (1) 25%   | 1*      |
| Twin-live birth rate                                                  | (0) 0%            | (1) 25%   | 1*      |
| Clinical pregnancy rate/fresh and frozen transfer                     | (2) 11.1%         | (6) 20%   | .69*    |
| Remaining frozen embryos (%)                                         | 16.7%             | 22.7%     | 1*      |
| Cumulative live birth rate                                            | (1) 4.5%          | (5) 22.7% | .18*    |
| Cumulative clinical pregnancy rate                                     | (2) 9.1%          | (6) 27.2% | .24*    |

Note: “Women and Men HIV” were couples in which both partners were HIV-positive. HIV — human immunodeficiency virus type 1; IVF — in vitro fertilization; LH — luteinizing hormone; MII — metaphase II; PN — pronuclei.

* Values are (number of IVF cycles) average ± SD.
* Values are (number of IVF cycles) percentage.
* Student’s t-test.
* X2 test.
* Yates’ corrected X2.
* Fisher’s exact test.

Vienna. HIV and ART, a retrospective study. Fertil Steril Rep 2021.
cancellation rate, lower number of oocytes, and lower clinical transfer rate and oocyte retrieval rate in the “women HIV” group.

In our study, results found in couples composed of two HIV-positive partners were similar to those found in the group of couples in which only the woman was HIV-positive. Thus, the total dose of gonadotropins and the duration of stimulation were higher in HIV-positive couples compared with seronegative controls. The number of oocytes at the oocyte retrieval and the rate of fertilization were lower in HIV-positive couples. Despite a trend to the detriment of HIV-positive couples for the other parameters, no significant difference could be found in pregnancy outcomes, probably because of the small size of this subgroup. Few studies in the literature have investigated the outcomes of IVF cycles in these couples. However, despite this limited data, the results seemed to be pejorative for these couples. In their 2011 study, Santulli et al. (18) had higher cancellation rates and significantly lower clinical pregnancy rates by oocyte retrieval in HIV-infected female and male couples vs. controls. In 2017, Vanker Kem et al. (20) did not show any significant difference in the outcome of HIV couples compared with HIV-negative controls. However, a negative trend was found for HIV couples with a live birth rate of 3% vs. 12% in the control group ($P = .3$) and an evolutionary clinical pregnancy rate per transfer of 5% vs. 15% in the control group ($P = .28$). These nonsignificant results may be because of the reduced numbers of studied couples. Nevertheless, it can be hypothesized that in these couples, the most negative factor regarding ART outcomes was the seropositivity of the woman.

In our study, no significant difference was found in the “men HIV” group compared with the controls. In the literature, other studies reported no significant difference between IVF results between HIV men versus controls (18, 24). In 2009, a case-control study found higher rates of pregnancy and implantation in the “men HIV” group compared with controls (25). Another study, in 2017 (20), found clinical pregnancy rates comparable to controls despite a lower fertility rate in the “men HIV” group. Overall, the literature seems reassuring concerning IVF results when HIV-positive men are compared with a population of uninfected controls. Thus, HIV infection or the use of antiretroviral treatment would not affect the sperm fertility capacity of HIV-positive men (when infection is controlled, a necessary condition for access to ART).

One of the first hypotheses that we can put forward is the toxicity of antiretroviral treatments, and in particular, the undesirable effects of nucleoside inhibitors on the mitochondria (29, 30), which would thus alter the oocyte quality. NRTIs inhibit HIV replication with their high affinity for viral DNA polymerase. However, they might also inhibit similar human structures such as the mitochondrial DNA polymerase, leading to a dysfunctional mitochondrial protein. Key metabolic functions are therefore no longer provided by the mitochondria, notably the oxidative phosphorylation, leading to an accumulation of reactive oxygen species. In 2008, Lopez et al. (31) found objective mitochondrial DNA depletion in oocytes of seropositive patients treated with nucleoside inhibitors. In addition, results to the detriment of HIV-positive women were found in a study conducted by Mataró et al. (32) on cycles with oocyte donation in HIV vs. non-HIV patients, suggesting that infection or antiretroviral therapy may also affect endometrial receptivity. One possible hypothesis to advance would be that this is a consequence of the inflammatory process associated with HIV (33) (alteration of coagulation, monocytic activation, and elevation of interleukins), which would disturb the exchanges between the endometrium and the embryo (34). This alteration in the implantation and the continuous inflammatory process might cause other complications during pregnancy such as miscarriage and intrauterine growth retardation (35). On the other hand, with identical ovarian reserve, the ovarian response was worse in HIV-positive women. Some investigators suggested possible indirect effects of antiretroviral therapy and HIV infection on the process of folliculogenesis (36, 37). Indeed, antiretroviral therapy, and especially PI, have been associated with the modification of lipid metabolism and insulin resistance, which may impact the regulation of ovulation and folliculogenesis. The infection of the gland itself, or systemic effects of HIV, can cause endocrine abnormalities as well, such as hormonal deficiencies (36). Antiretroviral therapy is known to have negative consequences on the metabolism of individuals (37). However, we know that these metabolic disorders also have an impact on the fertility of women (38). Protease inhibitors can have other deleterious effects, notably on decidualization and embryo implantation. In 2020, Kala et al. (39) found that lopinavir impaired uterine decidualization and spiral artery remodeling in human ex vivo and mouse in vivo experimental models, which caused defective maturation of the endometrium and thus poorer birth outcomes.

Another hypothesis that we can put forward is that comorbidities resulting from HIV infection can affect fertility as well. Immunosuppression resulting from HIV infection promotes the development of sexually transmitted infections, which tend to be more severe and more complicated to treat. Other opportunistic infections such as vaginitis, balanitis, and orchiepididymitis may affect fertility as well.

By taking into account the side-effects of antiretroviral therapy with regard to IVF outcomes, we wonder what consequences PrEP could have on pregnancy chances. A randomized trial published in 2016 was rather reassuring on this subject and showed that there was no increase in pregnancy loss or congenital anomalies in HIV seronegative women using PrEP during the peri-conception period (40). The duration of the treatment could be an important factor to take into account. In our study, we were unable to assess the effects of PrEP on IVF outcomes because none of our HIV-negative patients used this treatment. In light of our results and the literature, randomized controlled trials would be necessary to clarify the repercussions of HIV infection on IVF outcomes.

CONCLUSION

Since 2013 and following the latest updates of 2015 and 2018, French experts in the Morlat report (2, 41) and international experts (42, 43) recommend the use of natural conception when HIV infection is controlled. The orientation of couples toward ART is more motivated by the problem of infertility.
Given our results, as well as data from the literature, it seems important to consider HIV infection as a factor aggravating infertility, especially among women. The desire for children should be addressed early in the care of couples living with HIV to provide comprehensive information on the chances of pregnancy, fertility assessment, and the possibilities of care, if necessary. For men infected with HIV, the infection does not seem to compromise fertility. Thus, reassuring information should be given as to the chances of pregnancy for these couples. Further studies will be needed to understand the mechanisms involved in this phenomenon.

REFERENCES

1. Sidibé M. UNAIDS data 2018. Available at: https://www.unaids.org/sites/default/files/media_asset/unaids-data-2018-en.pdf. Accessed December 11, 2020.

2. Blanc A, Bonnet F, Brun-Vezinet F, Costagliola D, Dabis F, Delobel P, et al. Groupe d’experts pour la prise en charge du VIH. 2018;52. Available at: https://www.vihsante.ch/docs/201804/experts-vih_prevention-depistage.pdf. Accessed December 11, 2020.

3. Santé Publique France. Bulletin de santé publique. 2018;14. Available at: https://www.santepubliquefrance.fr/maladies-et-traumatismes/infections-sexuellement-transmissibles/vih-sida/documents/bulletin-national/bulletin-de-sante-publique-vih-sida-octobre-2019.pdf. October 9, 2019.

4. Molina J, Carmen del Gonzalvo M, Clavero A, Ángel López-Ruiz M, Mozas J, Pasquau J, et al. Assisted reproductive technology and obstetric outcome in couples when the male partner has a chronic viral disease. Int J Fertil Steril 2014;7:291–300.

5. Zafer M, Horvath H, Mmeje O, van der Poel S, Semprini AE, Rutherford G, et al. Effectiveness of semen washing to prevent human immunodeficiency virus (HIV) transmission and assist pregnancy in HIV-discordant couples: a systematic review and meta-analysis. Fertil Steril 2016;105:645–55.e2.

6. Loutfy MR, Wu W, Letchumanan M, Bondy L, Antoniou T, Margolese S, et al. Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PloS One 2013;8:e55747.

7. Sauer MV, Wang JG, Douglas NC, Nakhruda GS, Vardhana P, Jovanovic V, et al. Providing fertility care to men seropositive for human immunodeficiency virus: reviewing 10 years of experience and 420 consecutive cycles of in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril 2009;91:2455–60.

8. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2018. 25. Available at: https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-25-2.pdf. Accessed December 11, 2020.

9. Mandelbrot L, Tubiana R, Le Chenadec J, Dollfus C, Faye A, Pannier E, et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis 2015;61:1715–25.

10. Massad LS, Springer G, Jacobson L, Watts H, Anastos K, Korn A, et al. Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS 2004;18:281–6.

11. Dulioust E, Du AL, Costagliola D, Guibert J, Kunstmann J-M, Heard I, et al. Semen alterations in HIV-1 infected men. Hum Reprod 2002;17:2112–8.

12. Savasi V, Pari S, Oneta M, Laoreti A, Parrilla B, Duca P, et al. Effects of highly active antiretroviral therapy on semen parameters of a cohort of 770 HIV-1 infected men. PloS One 2019;14:e0212194.

13. Oh J, Partisani M, Witterer C, Schmitt MP, Crange C, Stoll-Keller F, et al. Assisted reproduction techniques for HIV serodiscordant couples: 18 months of experience. Hum Reprod 2003;18:1244–9.

14. Oh J, Partisani M, Witterer C, Lang JM, Vivile S, Favre R. Encouraging results despite complexity of multidisciplinary care of HIV-infected women using assisted reproduction techniques. Hum Reprod 2005;20:3136–40.

15. Wu MY, Chang LI, Chen MJ, Chao KH, Yang YS, Ho HH. Outcomes of assisted reproductive techniques for HIV-1-discordant couples using thawed washed sperm in Taiwan: comparison with control and testicular sperm extraction/vanoscopic epididymal sperm aspiration groups. J Formos Med Assoc 2011;110:495–500.

16. Giles M, Mijch A, Garland S. Assisted reproduction for HIV-infected couples. Sex Health 2005;2:223–7.

17. Coll O, Suy A, Figueras F, Vernaevve M, Martínez E, Mataró D, et al. Decreased pregnancy rate after in-vitro fertilization in HIV-infected women receiving HAART. AIDS 2006;20:121–3.

18. Santulli P, Gayet V, Fauque P, Chopin N, Dulioust E, Wolf JP, et al. HIV-positive patients undertaking ART have longer infertility histories than age-matched control subjects. Fertil Steril 2011;95:507–12.

19. Stora C, Epelboin S, Devouche E, Matheson R, Epelboin L, Yazbeck C, et al. Women infected with human immunodeficiency virus type 1 have poorer assisted reproduction outcomes: a case-control study. Fertil Steril 2016;105:1193–201.

20. Vankerem P, Manigart Y, Delvigne A, Ameye L, Konopnicki D, Shaw-Jackson C, et al. In vitro fertilization when men, women, or both partners are positive for HIV: a case-control study. Arch Gynecol Obstet 2017;295:1493–507.

21. Martinet V, Manigart Y, Rozenberg S, Becker B, Gerard M, Delvigne A. Ovarian response to stimulation of HIV-positive patients during IVF treatment: a matched, controlled study. Hum Reprod 2006;21:1212–7.

22. Terron P, Auquier P, Chabert-Orsini V, Chincholle JM, Cravello L, Giorgetti C, et al. Outcome of ICSI in HIV-1-infected women. Hum Reprod 2005;20:2838–43.

23. Noorden SK, Grossman LC, Bourne L, Guamaccia MM, Sauer MV, Douglas NC. Reproductive outcomes of HIV seropositive women treated by assisted reproduction. J Womens Health (Larchmt) 2013;22:243–9.

24. Prisant N, Tubiana R, Lebeyre L, Lepráy M, Marcelin AG, Thibault V, et al. HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome. Fertil Steril 2010;93:1020–3.

25. Kashima K, Takakuwa K, Suzuki M, Makino M, Kaneko S, Kato S, et al. Studies of assisted reproduction techniques (ART) for HIV-1-discordant couples using washed sperm and the nested PCR method: a comparison of the pregnancy rates in HIV-1-discordant couples and control couples. Jpn J Infect Dis 2009;62:173–6.

26. Agence de la biomédecine. La rapport médical et scientifique de l’Agence de la biomédecine. Available at: https://www.agence-biomedecine.fr/annexes/bilan2017/donnees/procreation/01-amp/synthese.htm. Accessed December 11, 2020.

27. Arrêté du 30 juin 2017 modifiant l’arrêté du 11 avril 2008 modifié relatif aux règles de bonnes pratiques cliniques et biologiques d’assistance médicale à la procréation. Available at: https://www.agence-biomedecine.fr/MG/ptd/20170630_rbpamp.pdf. Accessed June 30, 2017.

28. Manigart Y, Rozenberg S, Barlow P, Gerard M, Thibault V, et al. HIV-1 or hepatitis C chronic infection in serodiscordant infertile couples has no impact on infertility treatment outcome. Fertil Steril 2010;93:1020–3.

29. Margolis AM, Veerling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J Med Toxicol 2014;10:26–39.

30. Kushnir VA, Lewis W. Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals. Fertil Steril 2011;96:546–53.

31. López S, Coll O, Durban M, Hernández S, Vidal R, Suy A, et al. Mitochondrial DNA depletion in oocytes of HIV-infected antiretroviral-treated infertile women. Antivir Ther 2008;13:833–8.

32. Matárová D, García D, Coll O, Vassena R, Rodríguez A. Lower endometrial receptivity in HIV-infected women receiving oocyte donation: a comorbidity of HIV infection? Hum Reprod Open 2017;2017:hxo019.

33. Neuhus J, Jacobs DR, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010;201:1788–95.

34. Funderburg NT. Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Curr Opin HIV AIDS 2014;9:80–5.

35. European Collaborative Study, Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000;14:2913–20.
36. Englert Y, Lesage B, Van Vooren J-P, Liesnard C, Place I, Vannin A-S, et al. Medically assisted reproduction in the presence of chronic viral diseases. Hum Reprod Update 2004;10:149–62.

37. Bhasin S, Singh AB, Javanbakht M. Neuroendocrine abnormalities associated with HIV infection. Endocrinol Metab Clin North Am 2001;30:749–64, viii.

38. Lagathu C, Béreziat V, Gorwood J, Fellahi S, Bastard J-P, Vigouroux C, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with HIV antiretroviral treatment. Expert Opin Drug Saf 2019;18:829–40.

39. Kala S, Dunk C, Acosta S, Serghides L. Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies. Hum Reprod 2020;35:1781–96.

40. Heffron R, Pintye J, Matthews LT, Weber S, Mugo N. PrEP as peri-conception HIV prevention for women and men. Curr HIV/AIDS Rep 2016;13:131–9.

41. Morlat P, France, Conseil national du SIDA, France, Ministère des affaires sociales et de la santé, Agence nationale de recherches sur le sida (France). Prise en charge médicale des personnes vivant avec le VIH: rapport 2013 [pour le] Ministère des affaires sociales et de la santé: recommandations du groupe d’experts. Paris: la Documentation française; 2013. Available at: https://solidarites-sante.gouv.fr/MG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf. Accessed September 26, 2013.

42. Dumitru G, Irwin K, Tailor A. Updated federal recommendations for HIV prevention with adults and adolescents with HIV in the United States: the pivotal role of nurses. J Assoc Nurses AIDS Care 2017;28:8–18.

43. Centers for Disease Control and Prevention HR and SA National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, International Association of Providers of AIDS Care, Urban Coalition for HIV/AIDS Prevention Services. Recommendations for HIV prevention with adults and adolescents with HIV in the United States, 2014; 2014.